OHSU

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

NMDP Announces Enrollment of First Patient in OPTIMIZE Clinical Trial

Retrieved on: 
Tuesday, February 20, 2024
Haematopoietic system, Incidence, Bone marrow, Senior, Infection, Toxicity, MMUD, HCT, Malignancy, Graft-versus-host disease, Quality of life, ACCESS, GVHD, Safety, NMDP, Health, Patient, OHSU, Survival, Clinical trial, Health equity, Research, Vaccine

The trial is sponsored by NMDP through the Center for International Blood and Marrow Transplant Research (CIBMTR®).

Key Points: 
  • The trial is sponsored by NMDP through the Center for International Blood and Marrow Transplant Research (CIBMTR®).
  • The OPTIMIZE trial hypothesizes that a reduced PTCy dosage could reduce these risks while still effectively guarding against GvHD.
  • The OPTIMIZE trial’s goals include:
    Improve patient survival and quality of life by decreasing acute and long-term toxicities associated with standard dose PTCy.
  • This trial recently completed enrollment in its adult arms ahead of schedule and is continuing to enroll within its pediatric arm.

Healthcare Management Administrators Names Aadam Hussain as Chief Executive Officer and President

Retrieved on: 
Wednesday, January 17, 2024
Change Healthcare, HMA, OHSU, Culture, Partnership, University, Growth, Strategic planning, Cambia Health Solutions, Creativity, SVP, American Cancer Society, Management

BELLEVUE, Wash., Jan. 17, 2024 /PRNewswire/ -- Healthcare Management Administrators is pleased to welcome Aadam Hussain as its next president and chief executive officer to lead the company into its next phase of growth.

Key Points: 
  • BELLEVUE, Wash., Jan. 17, 2024 /PRNewswire/ -- Healthcare Management Administrators is pleased to welcome Aadam Hussain as its next president and chief executive officer to lead the company into its next phase of growth.
  • Hussain brings extensive healthcare experience to the role with a career spanning nearly two decades that focused on M&A integration, strategic planning, investing, and scaling businesses.
  • Prior to Cambia, he held numerous executive level roles with Change Healthcare, a healthcare technology company, and Health Evolution Partners, a healthcare focused private equity firm.
  • Hussain will succeed Lindsay Harris, who has been appointed chief commercial officer at Cambia Health Solutions, and who served as HMA's leader since 2020.

Seattle Reproductive Medicine Welcomes Dr. Amanda Hurliman to Its Esteemed Team

Retrieved on: 
Tuesday, January 9, 2024
Dream, Family, Hope, University, Patient, Fertility, Life, Health, OHSU, Pacific Northwest, REI, Dog, SRM, Empathy, Education, Pinnacle, Birth control

SEATTLE, Jan. 9, 2024 /PRNewswire/ -- Seattle Reproductive Medicine (SRM), a premier provider of reproductive health services within the Pinnacle Fertility network, proudly welcomes Dr. Amanda Hurliman, a compassionate and skilled specialist in Reproductive Endocrinology and Infertility (REI), to its esteemed team.

Key Points: 
  • SEATTLE, Jan. 9, 2024 /PRNewswire/ -- Seattle Reproductive Medicine (SRM), a premier provider of reproductive health services within the Pinnacle Fertility network, proudly welcomes Dr. Amanda Hurliman, a compassionate and skilled specialist in Reproductive Endocrinology and Infertility (REI), to its esteemed team.
  • "I am thrilled to join the team at Seattle Reproductive Medicine and look forward to continuing my journey in helping individuals and couples achieve their dreams of building a family," shares Dr. Hurliman.
  • "We are thrilled to welcome Dr. Amanda Hurliman to our team at Seattle Reproductive Medicine," said Dr. Nancy Klein.
  • Dr. Hurliman will serve patients in both Seattle and Bellevue, bringing her invaluable insight and heartfelt commitment to each person's unique journey.

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Science, Neoplasm, Patient, FDA, Gemcitabine, Progression-free survival, Biomarker, FOLFIRI, Oregon Health & Science University, PLK1, Knight Cancer Institute, Oregon Health and Science University Center for Women's Health, Clinical uses of mesenchymal stem cells, Pfizer, Cancer, OHSU, University of Pittsburgh Medical Center, CRDF, PT, SAN, ORR, University, SOC, Safety, Dicarboxylic acid, Investment, PR, Pharmaceutical industry, Cryptocurrency

"This has been a transformational quarter for Cardiff Oncology.

Key Points: 
  • "This has been a transformational quarter for Cardiff Oncology.
  • Contingent upon the results of CRDF-004, Cardiff Oncology plans to initiate CRDF-005, a Phase 3, randomized trial with registrational intent.
  • As of September 30, 2023, Cardiff Oncology had approximately $81.4 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on November 2, 2023.

Oregon Health & Science University (OHSU) to utilize RayStation technology for radiation therapy planning

Retrieved on: 
Tuesday, October 31, 2023
Cancer, Medicine, Patient, RaySearch Laboratories, Health, OHSU, Research, Medical device, Accuray, Physics, Q3

The center intends to implement adaptive therapy to acquire daily patient images and perform treatment adaptations such that the patient's treatment is optimized.

Key Points: 
  • The center intends to implement adaptive therapy to acquire daily patient images and perform treatment adaptations such that the patient's treatment is optimized.
  • OHSU and RaySearch consider this approach to precision medicine to be the future of radiation therapy.
  • Dr. John Bayouth, Vice Chair, Director of Physics and Chief Medical Physicist at OHSU says: "OHSU is building the organization's technological platforms for advanced radiation therapy.
  • Johan Löf, founder and CEO, RaySearch, says: "I am greatly encouraged that OHSU will integrate RayStation with Radixact, marking another step forward in our commitment to advancing radiation technology.

New Study Using Biological Dynamics’ ExoVerita Platform Validates Exosome Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC)

Retrieved on: 
Thursday, October 19, 2023
Managed Care, Research, Other Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, Neoplasm, Survival, Biomarker, II, Oregon Health & Science University, Exosome, Detection, Cell, Nanoparticle, Biological Dynamics of Forest Fragments Project, Disease, Cancer, OHSU, Machine learning, Survival rate, Pancreatic cancer, PDAC, Pharmaceutical industry, Medical imaging, Verita

Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.

Key Points: 
  • Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “ Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma .” The research demonstrates the effectiveness of exosome-isolation technology in detecting Stage I and II pancreatic ductal adenocarcinoma (PDAC), using an independent validation cohort.
  • Biological Dynamics’ ExoVita Pancreas assay, powered by the ExoVerita™ platform, uses the AC Electrokinetics method for exosome isolation.
  • “Driven by our Verita technology, the ExoVita test can detect challenging diseases like pancreatic cancer earlier than ever.
  • With further testing in real-world settings, we are confident our exosome enabled test will be useful for high-risk surveillance and early detection of pancreatic cancer, resulting in improved patient outcomes.”

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Retrieved on: 
Tuesday, September 26, 2023
Dicarboxylic acid, Pancreatic cancer, Carcinoma, IIT, CRDF, Progression-free survival, Serum, Phase II, Neoplasm, Clinical uses of mesenchymal stem cells, Gemcitabine, PT, SOC, Biomarker, PLK1, SCLC, Oregon Health and Science University Center for Women's Health, MD, Standard of care, Patient, SAN, OHSU, Cancer, Knight Cancer Institute, ORR, Oregon Health & Science University, PR, Safety, Pharmaceutical industry, PDAC

In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting."

Key Points: 
  • In small cell lung cancer, we are encouraged to observe single-agent activity with onvansertib monotherapy in this difficult-to-treat extensive stage refractory setting."
  • "We will continue to explore onvansertib in the first-line mPDAC investigator-initiated trial at the OHSU Knight Cancer Institute."
  • In cohort 2, patients will receive 10 days of onvansertib monotherapy followed by onvansertib + SoC to identify biomarkers that predict response to onvansertib.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 5:00 p.m. ET/2:00 p.m. PT on September 26, 2023.

David Huang, M.D., Ph.D., receives Lasker Award for transformative imaging technology

Retrieved on: 
Thursday, September 21, 2023
Heart, CT, Lasker-DeBakey Clinical Medical Research Award, Lasker Award, Oregon Health & Science University, Skin, Biomedical Research, Brain, Paratriathlon, Research, Disease, Biomedical engineering, Medicine, MRI, OHSU, Ophthalmology, OCT, Nobel, ARD International Music Competition, Diagnosis, Lasker, COOL, News, Eye disease, Massachusetts Institute of Technology, Medical imaging, Pharmaceutical industry, Nobel Prize

PORTLAND, Ore., Sept. 21, 2023 /PRNewswire/ -- The United States' most distinguished biomedical research award is being given to Oregon Health & Science University physician-scientist David Huang, M.D., Ph.D., for co-inventing an imaging technology that routinely helps prevent blindness and is increasingly used to diagnose and treat conditions of the heart, brain, skin and more.

Key Points: 
  • Huang is receiving the 2023 Lasker-DeBakey Clinical Medical Research Award as a co-inventor of optical coherence tomography, or OCT, the Albert and Mary Lasker Foundation has announced .
  • "I am proud that millions of people have benefited from a technology that I helped invent three decades ago."
  • Lasker prizes are sometimes referred to as "America's Nobels," as 95 Lasker award winners have gone on to receive the Nobel Prize.
  • Huang shares this year's Lasker-DeBakey award with fellow OCT co-inventors James G. Fujimoto, Ph.D., and Eric A. Swanson, M.S., both of the Massachusetts Institute of Technology.

GIGI'S PLAYHOUSE DOWN SYNDROME ACHIEVEMENT CENTER SIGNS SEVEN-YEAR LEASE TO SERVE PORTLAND, OREGON

Retrieved on: 
Wednesday, August 30, 2023
Test management, Responsibility, Get Ready, Playhouse, FREE, Drug, Down syndrome, Literacy, Child development, Gigi, Community, MD, Cost, Edward, Child, OHSU, Toy

This new location marks the 58th GiGi's Playhouse across the U.S. and Mexico and will offer educational, therapeutic, and career development programs from prenatal diagnosis through adulthood.

Key Points: 
  • This new location marks the 58th GiGi's Playhouse across the U.S. and Mexico and will offer educational, therapeutic, and career development programs from prenatal diagnosis through adulthood.
  • According to Brad Johnson, Board President GiGi's Playhouse Portland, LLC, "GiGi's programs help fill the informational, educational, therapeutic, and career training gaps experienced by individuals living with Down syndrome and their families."
  • Cost is never a barrier to achievement at GiGi's Playhouse, as programs are offered FREE to families.
  • "GiGi's Playhouse programs around the country have been wonderful resources for individuals with Down syndrome and their families.